U.S. President Donald Trump heads to Pittsburgh, Pennsylvania on Friday to headline a rally to celebrate Nippon Steel's ...

The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...

GILD stock jumps 21.1% YTD as HIV dominance, lenacapavir progress, and liver drug approval offset oncology pressures. However ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

Shares of Gilead Sciences, Inc. (GILD) were in the spotlight on Friday morning after the company reportedly said that it ...

Gilead Sciences, Inc. GILD announced positive top-line results from yet another late-stage study on breast cancer drug, ...

A key component of Gilead’s strategy is the development of lenacapavir, a long-acting HIV treatment and prevention option. Lenacapavir, slated for launch as a pre-exposure prophylaxis (PrEP ...

A key component of Gilead’s strategy is the development of lenacapavir, a long-acting HIV treatment and prevention option. Lenacapavir, slated for launch as a pre-exposure prophylaxis (PrEP) treatment ...

The company’s pipeline candidate, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women. The FDA accepted new drug application submissions for ...